BRAF and melanoma: Particularly, nucleotide changes at positions −138_139 CC>TT in TERT promoter have been shown to correlate with poorer clinical outcome in stage I and stage II melanoma patients, mainly in association with BRAF and NRAS mutations (Andrés-Lencina et al., 2019).